Welcome to CrystecPharma
CrystecPharma applies the latest supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.
Applications of our technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics.
Our solutions include the following:
- Crystal and particle engineering
- Stabilisation of therapeutic agents derived from biotechnology
- Polymorph screening
- Improved performance of poorly soluble drugs
- Inhaled therapy
- Taste masking
- Crystallisation seeds
- Residual solvent elimination
Bio-Europe, Cologne 2016
Crystec are attending Bio-Europe in Cologne in November. Contact us using the partnering system to schedule a meeting at the event.
September 29 2016
APS International PharmSci conference attended by Crystec’s CEO, Paul Thorning, and Chief Scientist, Professor Peter York
Crystec’s CEO, Paul Thorning, and Chief Scientist, Professor Peter York, were invited to present at the 7th APS International PharmSci conference last week. The event was hosted by the University of Strathclyde and focused on ‘Pharmaceutical Sciences: Improving World Health’.
September 12 2016
Crystec announces strategic partnership with the China Association of Traditional Chinese Medicine
Crystec are delighted to announce their partnership with the China Association of Traditional Chinese Medicine to accelerate the development of new and innovative Chinese medicines. The cooperation will allow Crystec to continue expanding the application of its proprietary supercritical fluid (SCF) particle engineering technology to improve the purity and quality of Traditional Chinese Medicines.
August 26 2016